ReviewPediatric research2025
Neurodevelopment in congenital heart disease: a review of antenatal mechanisms and therapeutic potentials.
Review in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects.Journal, genetic engineering & biotechnology · 2026Article
- Near-infrared spectroscopy cerebral oximetry in pediatric congenital heart disease with cardiopulmonary bypass: a narrative review of current evidence and neuroprotection.Frontiers in pediatrics · 2026Review
- The future of neurodevelopmental disabilities.Pediatric research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvements in treatment and survival of neonates with complex congenital heart disease have led to growing recognition of the associated neurodevelopmental impairments. In this review, we explore the possible antenatal mechanisms of altered brain development in these patients with particular focus on acquired and genetic risk factors. Hypoxia, placental pathology and maternal stress are acquired factors with therapeutic potential. Among the genetic and epigenetic mechanisms, we discuss the influences of angiogenic genes, chromatin modifiers, Wnt and Notch signalling pathways, chromosomal syndromes and apolipoprotein E alleles. Understanding these antenatal risk factors will allow for further development of currently experimental fetal therapies, such as maternal hyperoxygenation. IMPACT: Congenital heart disease has a substantial impact on neurodevelopmental outcome. This scoping review identifies and brings together overlapping genetic, environmental and hemodynamic antenatal mechanisms that impact on altered brain development. A better understanding of these mechanisms may lead to development of therapeutic potentials to improve neurodevelopment outcomes in this group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.